ES2174864T3 - Nuevos tratamientos que utilizan derivados de fenetilo. - Google Patents

Nuevos tratamientos que utilizan derivados de fenetilo.

Info

Publication number
ES2174864T3
ES2174864T3 ES94304252T ES94304252T ES2174864T3 ES 2174864 T3 ES2174864 T3 ES 2174864T3 ES 94304252 T ES94304252 T ES 94304252T ES 94304252 T ES94304252 T ES 94304252T ES 2174864 T3 ES2174864 T3 ES 2174864T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
disorder
syndrome
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94304252T
Other languages
English (en)
Inventor
Richard Leslie Rudolph
Albert Thomas Derivan
Eric Anthony Muth
Gertrude Virginia Upton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2174864(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2174864T3 publication Critical patent/ES2174864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA INVENCION SUMINISTRA EL USO DE UN COMPUESTO PARA PREPARAR UN MEDICAMENTO PARA TRATAR LA OBESIDAD, LAS ENFERMEDADES DE ANSIEDAD GENERALIZADA, LAS ENFERMEDADES DE ESTRES POSTRAUMATICOS, LOS DESORDENES DISFORICOS DE LA ULTIMA FASE LUTEAL (SINDROME PREMESTRUAL), DESORDENES DE FALTA DE ATENCION, CON O SIN HIPERACTIVIDAD, EL SINDROME DE GILLES DE LA TOURETTE, LA BULIMIA NERVIOSA O EL SINDROME DE SHY DRAGER. EL COMPUESTO ES UN AMINO DE HIDROXICICLOALCANOFENOETIL DE LA SIGUIENTE FORMULA ESTRUCTURAL: EN LA CUAL A ES UNA MOLECULA DE LA FORMULA: EN LA QUE LA LINEA PUNTEADA REPRESENTA UNA INSATURACION OPCIONAL; R1 ES HIDROGENO O ALQUIL; R2 ES ALQUIL; R4 ES HIDROGENO, ALQUIL, FORMIL O ALCANOIL; R5 Y R6 SON INDEPENDIENTEMENTE HIDROGENO, HIDROXIL, ALQUIL, ALCOXIDO, ALCANOILOXIDO, CIANO, NITRO, ALQUILMERCAPTO, AMINO, ALQUILAMINO, DIALQUILAMINO, ALCANOILAMINO, HALO, TRIFLUOROMETIL O TOMADAS JUNTAS DIOXIDO DE METILENO; R7 ES HIDROGENO O ALQUIL; Y N ES 0, 1, 2, 3 O 4; ASIMISMO SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DEL COMPUESTO.
ES94304252T 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilo. Expired - Lifetime ES2174864T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
ES2174864T3 true ES2174864T3 (es) 2002-11-16

Family

ID=22181084

Family Applications (3)

Application Number Title Priority Date Filing Date
ES01115854T Expired - Lifetime ES2273764T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.
ES94304252T Expired - Lifetime ES2174864T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilo.
ES06017469T Expired - Lifetime ES2304041T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01115854T Expired - Lifetime ES2273764T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06017469T Expired - Lifetime ES2304041T3 (es) 1993-06-28 1994-06-13 Nuevos tratamientos que utilizan derivados de fenetilamina.

Country Status (15)

Country Link
US (8) US5916923A (es)
EP (3) EP1738753B1 (es)
JP (2) JPH0789851A (es)
KR (1) KR100342762B1 (es)
AT (3) ATE342715T1 (es)
AU (2) AU6592994A (es)
CA (1) CA2126305C (es)
CY (1) CY2315B1 (es)
DE (3) DE69429895T2 (es)
DK (3) DK1153603T3 (es)
ES (3) ES2273764T3 (es)
HK (1) HK1038880B (es)
LV (1) LV12881B (es)
PT (3) PT1153603E (es)
SG (1) SG47711A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
SG49680A1 (en) * 1994-02-14 1998-06-15 American Home Prod Medicament for the inducement of cognition enhancement
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (en) * 1996-03-25 2015-08-26 Wyeth LLC Extended release formulation containing venlafaxine
CA2337507A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
CZ20013607A3 (cs) * 1999-04-06 2002-06-12 Sepracor Inc. Farmaceutický prostředek
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
IL150366A0 (en) * 1999-12-30 2002-12-01 Lundbeck & Co As H 4-phenyl-1-piperazinyl,-piperidinyl and tetrahydropyridyl derivatives
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002064543A2 (en) † 2001-02-12 2002-08-22 Wyeth Novel succinate salt of o-desmethyl-venlafaxine
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
EP1451145A1 (en) * 2001-12-05 2004-09-01 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
WO2003082262A2 (en) * 2002-03-28 2003-10-09 Synthon B.V. Compositions of venlafaxine base
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
WO2003082804A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
AU2003278549A1 (en) * 2002-11-28 2004-06-18 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
WO2006116149A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
GT200600164A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
US20070129562A1 (en) * 2005-10-19 2007-06-07 Kansal Vinod K Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride
JP5302005B2 (ja) * 2005-12-01 2013-10-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド セロトニン作動性および／またはノルエピネフリン作動性の活性を有する置換フェネチルアミン
JP2009518407A (ja) 2005-12-05 2009-05-07 ワイス 置換１−（２−アミノ−１−フェニル−エチル）−シクロヘキサノールのエナンチオマーを選択的に合成するための方法
AR060087A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento de la depresion
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CA2666350A1 (en) * 2006-10-25 2008-05-02 Wyeth Isolated hydroxy and n-oxide metabolites and derivatives of o-desmethylvenlafaxine and methods of treatment
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
US20090048233A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
WO2009065845A1 (en) * 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US20140116656A1 (en) * 2012-10-25 2014-05-01 Inhon International Co., Ltd Heat dissipation module and electronic device with the same
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
JP2938463B2 (ja) * 1987-10-22 1999-08-23 マサチユセツツ・インスチチユート・オブ・テクノロジー 月経前又は後期黄体期症候群の処置
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
FI910897A (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
ATE244563T1 (de) * 1991-11-15 2003-07-15 Sepracor Inc Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
US6444708B2 (en) 2002-09-03
ATE342715T1 (de) 2006-11-15
DE69435095D1 (de) 2008-06-05
LV12881B (en) 2002-11-20
EP0639374A3 (en) 1995-08-02
EP1153603B1 (en) 2006-10-18
PT639374E (pt) 2002-07-31
DE69435095T2 (de) 2009-07-02
DE69434872T2 (de) 2007-04-05
SG47711A1 (en) 1998-04-17
US20040110829A1 (en) 2004-06-10
US6310101B1 (en) 2001-10-30
EP1738753A2 (en) 2007-01-03
US5916923A (en) 1999-06-29
US6465524B2 (en) 2002-10-15
AU5831298A (en) 1998-05-21
ES2304041T3 (es) 2008-09-01
EP1153603A2 (en) 2001-11-14
CA2126305C (en) 2006-10-17
DE69429895D1 (de) 2002-03-28
ATE213407T1 (de) 2002-03-15
DK1738753T3 (da) 2008-08-11
PT1153603E (pt) 2007-01-31
JPH0789851A (ja) 1995-04-04
DE69429895T2 (de) 2002-08-29
AU6592994A (en) 1995-01-05
EP0639374B1 (en) 2002-02-20
US20020052405A1 (en) 2002-05-02
US20080176950A1 (en) 2008-07-24
EP1738753A3 (en) 2007-01-31
EP0639374A2 (en) 1995-02-22
KR100342762B1 (ko) 2002-11-18
US20010053799A1 (en) 2001-12-20
US6730706B2 (en) 2004-05-04
DK0639374T3 (da) 2002-05-06
US6555586B2 (en) 2003-04-29
KR950000139A (ko) 1995-01-03
CA2126305A1 (en) 1994-12-29
EP1738753B1 (en) 2008-04-23
JP2006117689A (ja) 2006-05-11
HK1038880B (zh) 2006-12-22
DK1153603T3 (da) 2006-12-18
PT1738753E (pt) 2008-06-19
ATE392893T1 (de) 2008-05-15
US20010012855A1 (en) 2001-08-09
HK1038880A1 (en) 2002-04-04
ES2273764T3 (es) 2007-05-16
CY2315B1 (en) 2003-11-14
US20030181517A1 (en) 2003-09-25
DE69434872D1 (de) 2006-11-30
EP1153603A3 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
ES2174864T3 (es) Nuevos tratamientos que utilizan derivados de fenetilo.
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
IT1283782B1 (it) Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
ES2037779T3 (es) Procedimiento para preparar nuevos compuestos de amida.
PL341281A1 (en) Novel acronicin compounds, method of obtaining them and pharmacological compoistions containing such compounds
ES554750A0 (es) Un procedimiento para la preparacion de derivados de fenoxietilamina
FI860074A0 (fi) Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel.
DK0667150T3 (da) Venlafaxin og dens analoger til fremkaldelse af en forbedring af de kognitive funktioner
ATE52776T1 (de) 1-phenyl-3-benzazepine.
MX9300782A (es) Proceso para preparar (5-amino-1,2-nihidro metil-3-fenilpirido[3,4-b]pirazin-7-7il) carbamato de etilo quiral
ECSP961994A (es) Acetidinas
BG100965A (en) New therapeutical injection-type analgetic pharmaceutical composition containing nimesulid (4-nitro, 2-phenoxyphenylmetanesulphonamide) for intramuscular administration and method for its preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639374

Country of ref document: ES